Intellia Therapeutics Inc

Intellia Therapeutics Inc

NTLA

Market Cap$880.46M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Intellia Therapeutics IncIntellia Therapeutics Inc-1.7--67%-0.2
$17.50

Target Price by Analysts

93.2% upsideIntellia Therapeutics Target Price DetailsTarget Price
$-5.18

Current Fair Value

157.2% downside

Overvalued by 157.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$880.46 Million
Enterprise Value$893.49 Million
Dividend Yield$0 (0%)
Earnings per Share$-5.25
Beta2.33
Outstanding Shares103,500,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-1.67
PEG-15.16
Price to Sales-
Price to Book Ratio1.29
Enterprise Value to Revenue20.74
Enterprise Value to EBIT-1.69
Enterprise Value to Net Income-2
Total Debt to Enterprise0.16
Debt to Equity0.18

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Intellia Therapeutics Inc

211 employees
CEO: John Leonard

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Th...